Zeneca Pharmaceutical's Accolate (zafirlucast), approved by the US Food and Drug Administration in September, is now available. The tablets are approved for twice-daily, oral administration for the prevention and treatment of chronic asthma in adults and children over the age of 12. The drug is a leukotriene receptor antagonist, the first of a new class of asthma drugs to be approved by the FDA in over 20 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze